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Abstract
Background: Dengue is a public health problem of global significance for which there is neither
an effective antiviral therapy nor a preventive vaccine. It is a mosquito-borne viral disease, caused
by dengue (DEN) viruses, which are members of the Flaviviridae family. There are four closely
related serotypes, DEN-1, DEN-2, DEN-3 and DEN-4, each of which is capable of causing disease.
As immunity to any one serotype can potentially sensitize an individual to severe disease during
exposure to a heterologous serotype, the general consensus is that an effective vaccine should be
tetravalent, that is, it must be capable of affording protection against all four serotypes. The current
strategy of creating tetravalent vaccine formulations by mixing together four monovalent live
attenuated vaccine viruses has revealed the phenomenon of viral interference leading to the
manifestation of immune responses biased towards a single serotype.
Results: This work stems from the emergence of (i) the DEN virus envelope (E) domain III (EDIII)
as the most important region of the molecule from a vaccine perspective and (ii) the adenovirus
(Ad) as a promising vaccine vector platform. We describe the construction of a recombinant,
replication-defective Ad (rAd) vector encoding a chimeric antigen made of in-frame linked EDIIIs
of DEN virus serotypes 2 and 4. Using this rAd vector, in conjunction with a plasmid vector
encoding the same chimeric bivalent antigen, in a prime-boost strategy, we show that it is possible
to elicit equipotent neutralizing and T cell responses specific to both DEN serotypes 2 and 4.
Conclusion: Our data support the hypothesis that a DEN vaccine targeting more than one
serotype may be based on a single DNA-based vector to circumvent viral interference. This work
lays the foundation for developing a single Ad vector encoding EDIIIs of all four DEN serotypes to
evoke a balanced immune response against each one of them. Thus, this work has implications for
the development of safe and effective tetravalent dengue vaccines.
Background
DEN viruses, of which there exist four distinct serotypes
(DEN-1, -2, -3 and -4), belonging to the family Flaviviri-
dae, are transmitted to humans by the mosquito Aedes
Published: 15 February 2007
BMC Biotechnology 2007, 7:10 doi:10.1186/1472-6750-7-10
Received: 23 August 2006
Accepted: 15 February 2007
This article is available from: http://www.biomedcentral.com/1472-6750/7/10
© 2007 Khanam et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Biotechnology 2007, 7:10 http://www.biomedcentral.com/1472-6750/7/10
Page 2 of 11
(page number not for citation purposes)
aegypti. Infection with DEN viruses poses a significant
public health threat to ~40% of the global population.
DEN virus infections, of which ~100 million cases occur
annually, produce symptoms ranging from mild fever to
severe hemorrhagic, potentially fatal, fever [1-3]. The
pathogenesis of severe disease is not very well understood.
Though several factors such as virulence of the infecting
virus, age and genetic predisposition of the patient are
implicated [4,5], the most important factor is held to be
sequential infection by different serotypes in areas of
endemicity [1-3]. Antibodies elicited by a given DEN virus
serotype, which confer lifelong homologous immunity to
that serotype, can cross-react with, but not protect against
the remaining serotypes. These in fact have the potential
to exacerbate disease severity through antibody depend-
ent enhancement (ADE), during secondary infection with
a different serotype [6,7]. Additionally, pre-existing mem-
ory T cell populations with lower avidity for the secondary
serotype may be responsible for sub-optimal viral clear-
ance and enhanced pro-inflammatory responses [8].
Therefore, an ideal dengue vaccine should be 'tetravalent',
capable of affording protection against all four DEN virus
serotypes [9,10].
In an effort to develop tetravalent dengue vaccines, several
investigators are currently exploring plasmid DNA-based
experimental vaccines in mice [11-13] and monkeys [14].
Simultaneously, some groups are also investigating
recombinant protein-based monovalent vaccine candi-
dates [15,16]. Of the numerous DEN vaccine approaches
being explored, live attenuated [17-23] and yellow fever
vaccine vector YF17D-based chimeric [24-27] vaccines are
in advanced stages of development [10,28]. Vector back-
bones based on attenuated DEN viruses are also being
used to develop intertypic chimeric vaccines [29,30]. Uni-
formly, all these vaccine candidates are 'monovalent' in
that they are specific to a single DEN virus serotype. All
these strategies rely on physically mixing the four mono-
valent vaccines to generate empirical 'tetravalent' formula-
tions [reviewed in [31,32]]. It is becoming increasingly
apparent that these formulations have the potential to
elicit a skewed immune response, predominantly to a sin-
gle serotype [18,23,25]. This has been attributed to 'viral
interference', a poorly understood phenomenon, associ-
ated with increased replication of one of the monovalent
vaccine viruses in the tetravalent formulation [reviewed in
[31,32]]. This has necessitated the testing of multiple,
empirical tetravalent formulations [20,22,27,30].
Recently, Zhou and Deem have suggested that injecting
the monovalent vaccines at separate sites may alleviate
this problem [33].
The objective of this work is to seek proof-of-concept for
the hypothesis that a single vaccine vector targeting multi-
ple DEN virus serotypes has the potential to bypass the
risk of viral interference inherent in the currently preva-
lent approach of mixing 'monovalent' vaccines. For this
purpose, we have developed a rAd vector encoding a novel
'bivalent' antigen, based on EDIII of DEN-2 and DEN-4
viruses. The choice of EDIII was based on several reasons.
First, EDIII has emerged as the most important domain
from a vaccine perspective. It has been shown that the
host cell surface receptor-binding motif of the E protein
maps to EDIII [34]; further serotype-specific multiple neu-
tralizing epitopes have been localized to this domain [35-
37]. Importantly, EDIII has only a very low intrinsic
potential for eliciting cross-reactive antibodies against
heterologous DEN virus serotypes [38,39], implicated in
severe pathogenesis. Second, DEN-2 virus EDIII protein
(EDIII-2) can block DEN-2 virus infectivity [40,41]. Third,
several groups [13,15,16,38,39] including ours [42,43]
have shown that EDIII-encoding gene-based vaccine can-
didates and recombinant EDIII fusion proteins elicit neu-
tralizing antibodies.
In this paper, we describe the construction and character-
ization of a bivalent rAd vector encoding a chimeric anti-
gen created by linking EDIIIs of DEN virus serotypes 2 and
4 (EDIII-4/2 antigen), and show that it elicits comparable
levels of virus-neutralizing antibodies and T cell responses
specific to these two serotypes.
Results
Creation of an EDIII-based bivalent antigen-encoding 
adenovirus vector, rAd-Bg
Two rAd vectors, shown in Figure 1A, were constructed for
this study. The test vector, rAd-Bg, carries the human
cytomegalovirus (CMV) promoter-driven chimeric EDIII-
4/2 antigen gene (derived by linking the EDIII-encoding
cDNAs generated from DEN-4 and DEN-2 viral genomic
RNAs) fused to a 3' green fluorescent protein gene (GFP)
tag, inserted into the Ad5 genome, in place of its E1
region. The control vector, rAd-C, is similar in design, with
the exception that it carries an empty CMV expression cas-
sette. Aliquots of the rAd viral DNA were subjected to PCR
analysis using Ad E1- and insert-flanking primers as
described earlier [42]. The results are shown in Figure 1B.
The E1-specific primers produced the predicted ~0.47 Kb
amplicon when the template was DNA from wild type
(wt) Ad (lane 2), but not when it was from either the rAd-
C (lane 3), or rAd-Bg (lane 4) viruses. PCR with insert-
flanking primers resulted in the amplification of a ~1.5 Kb
cDNA only from rAd-Bg (lane 8) but not from the wt Ad
DNA template (lane 6). From rAd-C viral DNA as the tem-
plate, the insert-flanking primers amplified a ~0.1 Kb vec-
tor derived cDNA product (lane 7). Extensive restriction
mapping of the rAd-C and rAd-Bg viral DNAs were found
to be consistent with the construction strategy (data not
shown).BMC Biotechnology 2007, 7:10 http://www.biomedcentral.com/1472-6750/7/10
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We next examined the ability of the rAd-Bg virus to
express the bivalent antigen by direct fluorescence micro-
scopy to detect its GFP tag. In the experiment shown in
Figure 2A, HEK 293 cells were observed ~24 hours after
infection with rAd-Bg (panel ii). Detection of the C-termi-
nal GFP tag suggests successful rAd-mediated expression
of the bivalent antigen. On the other hand, rAd-C virus-
infected cells (panel i), analyzed in parallel, did not dis-
play any green fluorescence. That the rAd-C virus had effi-
ciently infected the cells was evident from the
cytopathicity observed by visible light microscopy (data
not shown). In addition, we carried out indirect immun-
ofluorescence assays (IFA) to detect the EDIIIs corre-
sponding to DEN-2 and DEN-4 in the bivalent antigen. To
this end, we probed rAd-Bg infected cells, separately, with
monoclonal antibodies (mAbs) 3H5 and MAB8704 to
identify EDIIIs corresponding to DEN-2 and DEN-4,
respectively. As the bivalent antigen was GFP-tagged, we
used anti-murine IgG-rhodamine conjugate as the sec-
ondary antibody in the IFA experiment. 3H5 is a DEN-2
serotype-specific mAb, which specifically recognizes an
epitope that maps to amino acid (aa) residues 386–397 of
the E protein [44]. As this epitope falls within the DEN-2
EDIII region, this mAb is expected to recognize the rEDIII-
4/2 bivalent antigen as well. MAB 8704 is a DEN-4 virus-
specific mAb. We found that it was able to specifically rec-
ognize  E. coli-expressed DEN-4 EDIII (our unpublished
data). Thus, this mAb also is expected to recognize the
rEDIII-4/2 bivalent antigen. Consistent with this, probing
rAd-Bg infected cells with mAbs 3H5 (panel iii) and
MAB8704 (panel iv) resulted in red immunofluorescence.
We also identified the bivalent antigen in rAd-Bg virus-
infected cells using an immunoprecipitation approach
(Figure 2B). In this experiment, we used mAb 3H5 to
immunoprecipitate the bivalent antigen expressed in
infected HEK 293 cells. Consistent with the direct fluores-
The rAds constructed for this study Figure 1
The rAds constructed for this study. (A) Schematic representation of the linear genomes of the rAd-C and rAd-Bg 
viruses. The dashed line, close to the left end represents the position of region E1. The open box located towards the right end 
represents a ~2.7 Kb deletion in the non-essential E3 region (ΔE3). The hatched boxes at either end represent the left (L) and 
right (R) inverted terminal repeats (ITRs), and the open circle close to the L-ITR represents the packaging signal (ψ). In the 
rAds, region E1 is replaced either by an empty expression cassette (rAd-C) or the EDIII-4/2 expression cassette (rAd-Bg). 
Components of the expression cassettes are indicated by the following abbreviations, P: CMV promoter (the arrow indicates 
its orientation); 4 and 2: DEN-4 and DEN-2 EDIII-encoding regions, respectively, of the bivalent EDIII-4/2 gene; g: enhanced 
green fluorescent protein gene (fused in-frame to the EDIII-4/2 gene) and pA: SV40 polyadenylation signal. (B) Characterization 
of the rAd genomes by PCR. The picture depicts agarose gel analysis of PCR products generated using wt Ad5 (lanes 2, 6), 
rAd-C (lanes 3, 7) or rAd-Bg (lanes 4, 8) viral DNA templates. Primers used were either E1-specific (lanes 2–4) or specific to 
insert-flanking sequences (lanes 6–8). DNA size markers were run in lanes 1 and 5. Sizes of the lane 1 markers (in Kb) are indi-
cated to the left of the panel. The position of the 1.6 Kb band in lane 5 is indicated by a white dot for orientation. The arrows 
to the right indicate the positions of the amplicons corresponding to the bivalent insert (top), E1 region (middle) and the 
insert-less vector sequences (bottom).
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cence and IFA data, the 3H5 mAb specifically identified a
protein of the predicted size (~55 kDa) in rAd-Bg infected
(lane 4), but not in rAd-C infected (lane 2) and mock
infected (data not shown) HEK 293 cells. As a positive con-
trol, a parallel immunoprecipitation was performed using
cells infected with a previously reported rAd [45], express-
ing aa 1–395 of the DEN-2 virus E protein (lane 3). Taken
together, these data showed that the rAd-Bg virus is capa-
ble of expressing the intended chimeric bivalent antigen
in infected mammalian cells.
The bivalent antigen-induced antibodies recognize and 
neutralize the infectivity of DEN-2 and DEN-4, but not 
DEN-1 and DEN-3 viruses
A major objective of this study was to investigate if a single
rAd vector encoding an EDIII-based bivalent DEN antigen
would elicit antibodies specific to both the constituent
serotypes. To this end, we undertook mice immunization
experiments. As anti-Ad antibodies resulting from the ini-
tial immunization of the mice can potentially interfere
with the efficacy of the rAd vector to function as a vaccine
carrier during booster immunizations, we adopted a het-
erologous prime/boost strategy that entailed priming the
animals with the rAd vector, followed by boosting with a
plasmid vector encoding the same bivalent antigen gene.
Sera were collected periodically after priming and after
each boost. We performed two series of ELISAs using these
sera. In the first experiment, we determined antibody tit-
ers after each immunization, using the bivalent r-EDIII-4/
2 protein as the capture antigen, as shown in Figure 3A. It
is evident from the data presented that initial antibody tit-
ers which were relatively low, progressively increased after
each boost, with maximal titers being observed after the
final plasmid boost. In the next experiment, we analyzed
the capacity of sera obtained after the final boost, to spe-
cifically react with monovalent EDIII proteins corre-
sponding to each of the four DEN virus serotypes.
Accordingly, in this experiment antibody titers were deter-
mined using using rEDIII-1, rEDIII-2, rEDIII-3 and rEDIII-
4 proteins, as capture antigens. The results of this experi-
ment, depicted in Figure 3B, showed that serum from the
immunized animals manifested high levels of reactivity
towards the rEDIII proteins corresponding to DEN virus
serotypes 2 and 4, but not to serotypes 1 and 3.
To address the question if these antibodies would display
this serotype preference toward the DEN viruses them-
selves, we carried out an immunofluorescence-based
assay. BHK cells were separately infected with each of the
four DEN virus serotypes and probed with the test antise-
rum (obtained from rAd-Bg primed/bivalent plasmid
boosted animals) in conjunction with a secondary anti-
body-FITC conjugate. The prediction was that the test
antiserum should light up cells infected with DEN-2 and
DEN-4, but not DEN-1 and DEN-3 viruses. The results of
this experiment which substantiate this are presented in
Figure 4A. Panels in the first (a, e, i and m) and second (b,
f, j and n) columns depict the negative and positive con-
trols, respectively. DEN-1 (panel b), DEN-2 (panel f),
DEN-3 (panel j) and DEN-4 (panel n) viruses were
detected using murine polyclonal antibodies raised
against E. coli-expressed rEDIII-1, rEDIII-2, rEDIII-3 and
rEDIII-4 proteins, respectively. The detection of immun-
ofluorescence in panels b, f, j and n demonstrates that
DEN-1, 2, 3 and 4 viruses, respectively, had successfully
infected the cells in this experiment. Mock-infected cells
did not fluoresce with any of these antibodies (panels a, e,
i and m), indicating that the antibodies used are virus-spe-
cific. The control serum (obtained from rAd-C primed/
empty plasmid boosted animals) also resulted in no fluo-
rescence in DEN virus-infected cells (panels c, g, k and o).
This suggests that the vaccine vectors per se do not induce
a DEN virus-specific immune response. Consistent with
the ELISA data, the use of test serum as the source of pri-
mary antibodies in the assay resulted in the identification
of DEN-2 (panel h) and DEN-4 (panel p), but not DEN-1
(panel d) and DEN-3 (panel l) viruses, as predicted. Taken
together, the data strongly suggest that the bivalent EDIII-
4/2 antigen elicits antibodies that specifically recognize
DEN-2 and DEN-4 viruses with little evidence of cross-
reactivity towards DEN-1 and DEN-3 viruses.
While the data obtained so far indicated that the EDIII-4/
2 antigen induces a bivalent response targeting DEN-2
and DEN-4 viruses, it does not provide any information
regarding the capacity of these antibodies to neutralize
their infectivity. To this end, we performed plaque reduc-
tion neutralization tests (PRNTs), by plaqueing the anti-
body-incubated DEN viruses on LLCMK2 cells. Figure 4B
presents the percent reduction in virus infectivity as a
function of test serum dilution for each of the four DEN
virus serotypes. The data show that the test serum dis-
played PRNT50 titers of ~1:80 towards both DEN-2 and
DEN-4 viruses, with no significant neutralizing antibody
titers towards DEN-1 and DEN-3 viruses.
Induction of DEN-2 and DEN-4 virus-specific T cell 
responses
Spleen cells in culture, derived from control and test mice,
were stimulated in vitro with DEN-2 and DEN-4 viruses,
separately, and monitored for proliferation responses and
cytokine (IFN-γ and IL-4) production, as depicted in Fig-
ure 5. Splenocytes from test mice manifested significant
and similar levels of proliferation in response to in vitro
stimulation with both DEN-2 and DEN-4 viruses, com-
pared to mock-stimulated splenocytes (Figure 5A). Con-
trol splenocytes did not manifest any proliferative
response regardless of whether they were stimulated or
not. The proliferative response of the test splenocytes was
accompanied by IFN-γ secretion (Figure 5B). The elevatedBMC Biotechnology 2007, 7:10 http://www.biomedcentral.com/1472-6750/7/10
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levels of IFN-γ, first evident at 48 hours post stimulation,
persisted for the duration of the experiment. Again, as
seen in the thymidine uptake experiment, both DEN-2
and DEN-4 virus stimulation resulted in comparable lev-
els of IFN-γ production. At all time points tested, mock-
stimulated test cells did not secrete discernible levels of
IFN-γ. When control mouse spleen cell cultures were
tested, IFN-γ was barely detectable in mock- and virus-
stimulated culture supernatants. With regard to IL-4, the
splenocytes manifested an increase in the levels of IL-4
secretion in response to virus stimulation, but it was not
dramatic (as seen for IFN-γ), as basal IL-4 levels in control
splenocytes were somewhat elevated. The magnitude of
stimulation of IL-4 secretion in test splenocytes with
respect to mock-stimulated cells, which was about 2 fold
higher at 24 hours, increased to about 5 fold at 96 hours
(Figure 5C). Taken together, these experiments demon-
strate that the bivalent antigen, elicits DEN-2 and DEN-4
virus-specific T-cell responses. Interestingly, the magni-
tude of these responses was more or less equivalent for the
two serotypes.
Discussion
This work was driven by the hypothesis that switching
from a strategy reliant on mixing four monovalent atten-
uated RNA viruses to a single tetravalent DNA viral vac-
cine vector may provide a means of circumventing viral
interference and the associated risk of ADE. In this regard,
Ad, a DNA virus, is emerging as a promising vaccine plat-
form [46,47]. Recent data on the use of rAd vectors to
develop experimental HIV-1 vaccines are encouraging. As
a first step towards our objective, we recently showed that
a rAd vector harboring the DEN-2 E gene could elicit
DEN-2 virus-neutralizing antibodies in mice [45]. Subse-
quently, using EDIII of DEN-2 virus, in the context of the
rAd vector system, we showed that it was able to induce
DEN-2 virus-specific neutralizing antibodies and T cell
responses as effectively as the complete E protein [42]. In
the current study, we have created and analyzed a bivalent
rAd vector. The purpose of this work was to obtain proof
for the hypothesis that a single rAd-based dengue vaccine
vector could elicit a balanced immune response to more
than one DEN virus serotype.
We inserted a chimeric, EDIII-based bivalent gene, EDIII-
4/2, designed by splicing together cDNAs encoding EDIIIs
of DEN-2 and DEN-4 viruses [43], in place of the E1
region of the Ad5 genome to create a bivalent rAd vector.
Mice immunized with a single dose of bivalent rAd man-
ifested modest serum titers of antibodies to DEN-2 and
DEN-4 viruses. In order to avoid the possibility that anti-
Ad antibodies generated after rAd priming may compro-
mise the vector's efficacy during repeat inoculations, we
boosted the rAd primed mice with a plasmid encoding the
bivalent antigen. DEN virus-specific antibodies in the sera
of immunized animals were assessed by several criteria.
This showed that these sera contained antibodies that spe-
cifically recognized EDIII-2 and EDIII-4, but manifested
barely discernible reactivity towards EDIII-1 and EDIII-3.
The critical question that we addressed at this point was,
do these antibodies possess the capacity to neutralize, spe-
cifically, the infectivity of DEN-2 and DEN-4 viruses?
rAd-mediated expression of rEDIII-4/2 protein as aGFP fusion Figure 2
rAd-mediated expression of rEDIII-4/2 protein as aGFP fusion. (A) Detection of rAd-mediated bivalent antigen 
expression by fluorescence microscopy. HEK 293 cells were either infected with rAd-C (panel i), or rAd-Bg (panel ii-iv) for 24 
hours and examined either directly for GFP fluorescence (panels i and ii) or analyzed by IFA, using either mAb 3H5 (panel iii) or 
MAB8704 (panel iv), as the primary antibody in conjunction with rhodamine-conjugated anti-murine IgG as the secondary anti-
body. (B) Immunoprecipitation of the bivalent protein from infected HEK 293 cells. Cells were infected with rAd-C (lane 2), a 
rAd expressing DEN-2 E (lane 3 [ref. 45]) or rAd-Bg (lane 4) viruses. Infected cells were metabolically labeled with [35S]-
methionine, lysed, immunoprecipitated with 3H5 mAb, and analyzed on a denaturing 15% polyacrylamide gel. Pre-stained pro-
tein markers were run on the same gel (lane 1); their sizes (in kDa) are indicated on the left. The arrows on the right show the 
positions of the bivalent protein (upper) and the E protein (lower).
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Using the rAd vector prime/plasmid boost strategy, DEN-
2 and DEN-4 virus-specific PRNT50 titers in the sera of
immunized mice were each ~1:80. Using monkeys, which
do not manifest dengue disease, protective efficacy is
measured in terms of reduction in viremia in animals
challenged with DEN virus. In the monkey model, it has
been reported that PRNT50 titers in the range of 1:20 to
1:80, in animals immunized with either pox virus vector
based-[48] or yellow fever virus-based [27] experimental
dengue vaccines, confer protection against live DEN-2
virus challenge. In the mouse model, again which does
not manifest any dengue disease, protective efficacy is
measured in terms of survival after lethal DEN virus chal-
lenge. As the volume of serum that one can obtain from
mice is quite small, PRNT assays are usually done using
pooled sera. Consequently, the precise neutralizing anti-
body titers in individual animals prior to challenge is not
known. Thus, the relationship between neutralizing anti-
body titers and protective efficacy has not been clearly
delineated in murine systems. However, in the absence of
a good animal model for dengue, neutralizing antibody
titers, determined by PRNT titers are widely accepted as
surrogate markers of protective immunity. PRNT50 titers =
1:10 are considered as indicative of protective immunity
[49,50].
Consistent with the design of the bivalent antigen, the
neutralizing antibodies it elicited specifically blocked the
infectivity of DEN-2 and DEN-4, but not that of DEN-1
and DEN-3 viruses. This essentially corroborates our pre-
vious findings using a bacterially expressed recombinant
EDIII-4/2 bivalent antigen [43]. Further, the observed
immunogenicity of the EDIII-4/2 bivalent antigen either
without [43] or with the GFP tag (this study) suggests that
fusion of the reporter has not adversely affected its poten-
tial to elicit DEN-2 and DEN-4 virus-specific neutralizing
antibodies. The E. coli-expressed antigen which is insolu-
ble needs to be empirically re-folded subjecting antigen
preparations to variability. Further, protein antigens are
not efficient at inducing cell-based immunity (CMI).
Given that the structural integrity of EDIII is essential for
its immunogenicity, the gene-based vaccines (this study),
which eliminate this variability are far more desirable,
Reactivity of immune sera towards monovalent and bivalent rEDIII proteins Figure 3
Reactivity of immune sera towards monovalent and bivalent rEDIII proteins. (A) Antibody titers in serial dilutions 
of murine sera drawn 1 week after priming with rAd-Bg (blue) and 1 week following the first (red), second (green) and final 
(violet) boosts with pVAX-EDIII-4/2 plasmid were determined in an ELISA using the rEDIII-4/2 bivalent protein as the capture 
antigen. The black dashed curve indicates ELISA reactivity of control sera, drawn from rAd-C primed/pVAX1-boosted mice 
after the final boost. (B) Antibody titers in serial dilutions of murine sera drawn from rAd-Bg primed/pVAX-EDIII-4/2 boosted 
mice, one week after the final boost. ELISA was performed using rEDIII-1 (blue), rEDIII-2 (green), rEDIII-3 (red) and rEDIII-4 
(violet) proteins as capture antigens. The black dashed curve indicates ELISA reactivity of control sera using a mixture of the 
four rEDIII proteins as capture antigen. All ELISA values in this experiment represent the average of two separate determina-
tions.
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with the added advantage that these can also provoke
potent CMI.
Our previous [42,43] and current work suggests that EDIII
is serotype-specific and that it must be possible to evoke a
tetravalent response using a chimeric antigen containing
EDIIIs of all four DEN virus serotypes linked to each
other. While most recombinant approaches to dengue
vaccines deal primarily with monovalent vaccines,
recently a couple of tetravalent plasmid vaccine candi-
dates, both based on the full-length E protein genes, have
been reported. One is based on mixing four monovalent
plasmid vaccines [12], and the other describes a plasmid
encoding a single chimeric E gene generated by DNA shuf-
fling [11,14]. While both these are reported to elicit neu-
tralizing antibodies, it is difficult to correlate our data on
DEN-2 and DEN-4 PRNT titers with these studies as they
have employed homologous plasmid prime/plasmid
boost immunizations aside from differences in immuni-
zation schedules and neutralization assay protocols.
Experiments are underway to investigate the role of the
DEN-2 and DEN-4 virus-specific antibodies induced by
rAd-Bg immunization in affecting the replication of DEN-
1 and DEN-3 viruses.
Conclusion
Our data provide support for the hypothesis that a single
vector system encoding a bivalent EDIII-based antigen has
the capacity to induce a balanced immune response
against both parental serotypes, thereby circumventing
any potential possibility of immune interference. Thus,
our data suggest that one can envisage the creation of a
single antigen gene encoding EDIIIs of all four DEN virus
serotypes, which could be incorporated into a single rAd
vector to elicit a balanced tetravalent immune response.
From a technical standpoint, it would be well within the
Simultaneous induction of antibodies that recognize and neutralize DEN virus serotypes 2 and 4 Figure 4
Simultaneous induction of antibodies that recognize and neutralize DEN virus serotypes 2 and 4. (A) IFA of DEN 
virus-infected cells using murine antisera. BHK cells were either mock infected (panels a, e, i and m) or infected separately with 
DEN-1 (panels b, c, d), DEN-2 (panels f, g, h), DEN-3 (panels j, k, l) and DEN-4 (panels n, o, p) viruses. One day after infection, 
cells were fixed and probed separately with different antisera as the source of primary antibodies. The antisera were obtained 
from mice, immunized with purified recombinant proteins [rEDIII-1 (panels a, b), rEDIII-2 (panels e, f), rEDIII-3 (panels i, j), and 
rEDIII-4 (panels m, n)] and rAd/plasmid [rAd-C/pVAX1 (panels c, g, k, o) or rAd-Bg/pVAX-EDIII-4/2 (panels d, h, l, p)]. The 
resultant virus/antibody complexes were visualized using anti-mouse IgG-FITC conjugate. (B) LLCMK2 monolayers were sepa-
rately infected with each of the four DEN viruses (DEN-1: filled circles; DEN-2: filled squares; DEN-3: open circles; & DEN-4: 
open squares) that had been pre-incubated with serial two-fold dilutions of pooled immune serum drawn from the rAd-Bg 
primed/plasmid pVAX-EDIII-4/2 boosted animals. The resultant plaque counts, expressed as percent inhibition of virus infectiv-
ity (with reference to the number of plaques generated in the absence of antiserum, which was taken to represent 100% infec-
tivity) are plotted as a function of antiserum dilution. Each data point shown represents the mean of four replicate assays (the 
error bars represent SD).
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capacity of the currently used first generation rAd vectors
to accommodate the EDIIIs, but not the Es, of all four
DEN virus serotypes. Prior immunity to Ad5, beyond a
certain threshold, may compromise the efficacy of the
Ad5 vector. Nevertheless, it has served, as a model to test
our hypothesis, and it should be possible to switch to a
vector with low/no seroprevalence such as Ad35, chimp
Ad or adeno-associated virus in future.
Methods
Plasmids, viruses and cells
Plasmids pVAX1 was from Invitrogen. Plasmids pShuttle-
CMV and pAdEasy-1, designed for rAd vector construc-
tion, have been described previously [51]. DEN viruses
DEN-1 (Nauru Island), DEN-2 (New Guinea C), DEN-2
(H87) and DEN-4 (H241) were gifted by Dr. A. Falconar
(University of Oxford, Oxford, UK). Ad5 transformed
HEK 293 cell line, Baby Hamster Kidney (BHK 21) cell
line, the monkey kidney cell line LLCMK2, the mosquito
cell line C6/36, and the 3H5 mAb-producing hybridoma
cell line, HB46, were from American Type Culture Collec-
tion, Virginia, USA, and were propagated as described ear-
lier [42].
Preparation of DEN virus stocks
DEN virus stocks were prepared by infecting C6/36 cells at
low multiplicity for two weeks with media replacement at
one week. The resultant infected cell culture supernatant
was used as the source of DEN viruses. Viral titers were
determined by plaque assay on LLCMK2 cells [42,43].
Construction of rAd-C and rAd-Bg viruses
The design and construction of the bivalent gene, EDIII-4/
2, have been described previously [43]. This gene was
cloned into plasmid pVAX1 and verified to encode the
predicted ~28 kDa bivalent protein in a rabbit reticulocyte
expression system (TNT system from Promega). The 3' end
of this chimeric gene was fused in-frame with the 5' end of
the  GFP  gene and cloned into the Ad shuttle plasmid
pShuttle-CMV. The EDIII-4/2-GFP expression cassette was
then inserted into the E1 region of the Ad5 genome of
plasmid pAdEasy-1 by in vivo recombination in E. coli
BJ5183 [51]. The resultant rAd plasmid was digested with
Analysis of T cell responses elicited by the bivalent antigen Figure 5
Analysis of T cell responses elicited by the bivalent antigen. Splenocytes were obtained from mock-immunized (open 
bars) and test-immunized (gray, black and hatched bars) animals, 7 weeks after the final immunization and placed in culture. 
They were either mock-stimulated (open and gray bars) or stimulated in vitro, either with DEN-2 (black bars) or DEN-4 
(hatched bars) for 96 hours for performing the T cell assays. Tritiated [3H] thymidine uptake was determined in a scintillation 
counter (A). Aliquots of the culture supernatant withdrawn at the indicated time points were assayed for the presence of IFN-
γ (B) and IL-4 (C) by solid phase ELISA. Data depicted represent the mean value of three separate determinations (the error 
bars represent SD). In panel A, two dosage levels of virus were used for in vitro stimulation [L, low (0.015 PFU/cell); and H, high 
(0.03 PFU/cell); N, no antigen]. Data in panels B and C were generated using splenocytes stimulated with the high dose.
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Pac I to eliminate plasmid sequences and transfected into
HEK 293 cells to rescue the rAd-Bg virus. The rAd-C virus
was constructed in parallel using a similar strategy except
that empty pShuttle-CMV plasmid was used during in vivo
recombination in E. coli. Recombinant viruses were
amplified, purified on CsCl gradients, dialyzed against 1×
PBS containing 10% glycerol, sterilized using syringe fil-
ters and titrated on HEK 293 cells. Both viruses yielded
fairly comparable titers, within 3–4 folds of each other.
Detection of transgene expression in rAd-Bg virus-infected 
cells
HEK 293 cells were infected at ~25 PFU/cell, for ~24
hours. The expression of the GFP tag was detected by
direct fluorescence microscopy. The DEN-2 and DEN-4
EDIII components of the bivalent antigen were detected
by IFA, using mAb 3H5 (DEN-2 virus-specific) and
MAB8704 (DEN-4 virus-specific), in conjunction with
anti-murine IgG-rhodamine conjugate [42]. Expression of
the transgene was also detected in infected, [35S]-radiola-
beled cells by immunoprecipitation, using the 3H5 mAb
as described previously [42].
Mouse immunization
Balb/c mice (4–6 weeks old; 5 animals per group) were
immunized using a rAd prime/plasmid boost regimen.
The control group was injected intraperitoneally (i.p)
with 108 PFU of rAd-C vector (in 200 μl of 1× PBS), fol-
lowed 15 days later by three intradermal (i.d) doses, again
15 days apart, of 50 μg plasmid pVAX1 vector (in 200 μl
of 1× PBS). A similar regimen was followed for the test
group, which was primed i.p. with 108 PFU of rAd-Bg vec-
tor and boosted i.d. with 50 μg plasmid pVAX-EDIII-4/2
vector. Blood was drawn 1 week after priming and after
each boost for seroanalysis. Animal experiments were per-
formed after approval of the Institutional Animal Ethics
Committee.
Seroanalysis
Antibody titers in sera of immunized mice were deter-
mined by ELISA, in 96-well plates, using monovalent and
bivalent r-EDIII proteins or DEN viruses as capture anti-
gens in conjunction with anti-murine IgG-HRPO second-
ary antibody conjugate/3, 3' 5, 5' tetramethyl benzidine
substrate, as previously described [43]. The presence of
anti-DEN-2 and anti-DEN-4 virus antibodies in immune
sera (diluted 1:100) was also detected by IFA of DEN-2
and DEN-4 virus-infected BHK cells (0.1 PFU/cell) at 24
hours post-infection. Virus-bound antibodies were
detected using anti-mouse IgG-FITC conjugate as done
earlier [43]. Neutralizing antibody titers were determined
by standard PRNT assay using LLCMK2 cells as before
[42,43]. The antiserum dilution resulting in 50% reduc-
tion in plaque count (with reference to the number of
plaques generated by the virus in the absence of antise-
rum), was expressed as the PRNT50 titer.
T cell assays
Spleens were harvested from mice ~7 weeks after the last
immunization and cultured in 96-well plates for monitor-
ing proliferative response and cytokine secretion in
response to in vitro stimulation with DEN-2 and DEN-4
viruses (each at 0.03 PFU/cell). Cells were pulsed with
[3H]-thymidine overnight at the end of 96 hours, and pro-
liferation was quantitated by measuring the uptake of the
radioisotope in a scintillation counter. IFN-γ and IL-4
were determined in splenocyte culture supernatants, at
the indicated time points, using murine Quantikine
cytokine ELISA kits (R & D systems), as described previ-
ously [42,45]. All assays for T cell responses were run in
triplicate and values expressed as mean ± standard devia-
tion (SD).
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